This basic science study tests whether local injection of beige fibro-adipogenic progenitors (BAT-FAPs) can treat muscle degeneration after rotator cuff repair. Mice underwent supraspinatus tear with nerve transection, then delayed repair at 2 or 6 weeks with or without cell injection. It asks whether cell transplantation can reverse the fibrosis, fatty infiltration, and atrophy that repair alone cannot.
The core clinical lesson predates this paper but is reinforced by it: rotator cuff repair fixes the tendon, not the muscle. Fatty infiltration and atrophy do not reverse after repair, which is why high-grade Goutallier changes (class 3-4) predict retear and poor function. Preoperative FI is a prognostic marker you should factor into surgical decision-making.
The mechanistic insight worth carrying forward: FAPs are the shared cellular origin of both fibrosis and fatty infiltration. This makes them a rational therapeutic target.
This study shows that driving FAPs toward a beige, UCP-1-expressing phenotype, delivered locally, reduced degeneration and improved function even in delayed repair. Local delivery avoids the cardiovascular and antimuscarinic risks of systemic beta-3 agonists.
Temper expectations: this is a mouse model, Sca1 is a mouse-specific marker, and no human FAP marker is yet defined. This is early-stage translational science, not a current clinical option.
This basic science study tests whether local injection of beige fibro-adipogenic progenitors (BAT-FAPs) can treat muscle degeneration after rotator cuff repair. Mice underwent supraspinatus tear with nerve transection, then delayed repair at 2 or 6 weeks with or without cell injection. It asks whether cell transplantation can reverse the fibrosis, fatty infiltration, and atrophy that repair alone cannot.
The core clinical lesson predates this paper but is reinforced by it: rotator cuff repair fixes the tendon, not the muscle. Fatty infiltration and atrophy do not reverse after repair, which is why high-grade Goutallier changes (class 3-4) predict retear and poor function. Preoperative FI is a prognostic marker you should factor into surgical decision-making.
The mechanistic insight worth carrying forward: FAPs are the shared cellular origin of both fibrosis and fatty infiltration. This makes them a rational therapeutic target.
This study shows that driving FAPs toward a beige, UCP-1-expressing phenotype, delivered locally, reduced degeneration and improved function even in delayed repair. Local delivery avoids the cardiovascular and antimuscarinic risks of systemic beta-3 agonists.
Temper expectations: this is a mouse model, Sca1 is a mouse-specific marker, and no human FAP marker is yet defined. This is early-stage translational science, not a current clinical option.